Glenn F. Pierce M.D., Ph.D.
Net Worth
Last updated:
What is Glenn F. Pierce M.D., Ph.D. net worth?
The estimated net worth of Dr. Glenn F. Pierce M.D., Ph.D. is at least $483,660 as of 14 Jul 2022. He owns shares worth $59,430 as insider, has earned $63,730 from insider trading and has received compensation worth at least $360,500 in Voyager Therapeutics, Inc..
What is the salary of Glenn F. Pierce M.D., Ph.D.?
Dr. Glenn F. Pierce M.D., Ph.D. salary is $51,500 per year as Independent Director, Interim Chief Scientific Officer & Chief Medical Officer in Voyager Therapeutics, Inc..
How old is Glenn F. Pierce M.D., Ph.D.?
Dr. Glenn F. Pierce M.D., Ph.D. is 69 years old, born in 1956.
What stocks does Glenn F. Pierce M.D., Ph.D. currently own?
As insider, Dr. Glenn F. Pierce M.D., Ph.D. owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Voyager Therapeutics, Inc. (VYGR) | Independent Director, Interim Chief Scientific Officer & Chief Medical Officer | 16,788 | $3.54 | $59,430 |
What does Voyager Therapeutics, Inc. do?
Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, as well as for spinal muscular atrophy. The company has collaboration and license agreements with Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. for the research, development, and commercialization of adeno-associated virus gene therapy products. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
Glenn F. Pierce M.D., Ph.D. insider trading
Voyager Therapeutics, Inc.
Dr. Glenn F. Pierce M.D., Ph.D. has made only one insider trade between 2018-2022, according to the Form 4 filled with the SEC. He sold 9,512 units of VYGR stock worth $63,730 on 14 Jul 2022.
As of 14 Jul 2022 he still owns at least 16,788 units of VYGR stock.
Voyager Therapeutics key executives
Voyager Therapeutics, Inc. executives and other stock owners filed with the SEC:
- Dr. Glenn F. Pierce M.D., Ph.D. (69) Independent Director, Interim Chief Scientific Officer & Chief Medical Officer
- Dr. Steven M. Paul M.D. (74) Executive Science Advisor & Director
- Mr. G. Andre Turenne (51) Advisor
- Mr. Michael J. Higgins M.B.A. (63) Interim Chief Executive Officer, Pres & Chairman
- Mr. Robert W. Hesslein (72) Senior Vice President & Gen. Counsel